Yuan S - Search Results

1

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

Wang L, Jin H, Jochems F, Wang S, Lieftink C, Martinez IM, De Conti G, Edwards F, de Oliveira RL, Schepers A, Zhou Y, Zheng J, Wu W, Zheng X, Yuan S, Ling J, Jastrzebski K, Santos Dias MD, Song JY, Celie PNH, Yagita H, Yao M, Zhou W, Beijersbergen RL, Qin W, Bernards R. Wang L, et al. Among authors: yuan s. Nat Cancer. 2022 Nov;3(11):1284-1299. doi: 10.1038/s43018-022-00462-2. Epub 2022 Nov 22. Nat Cancer. 2022. PMID: 36414711

2

Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy.

Yang S, Yan HL, Tao QF, Yuan SX, Tang GN, Yang Y, Wang LL, Zhang YL, Sun SH, Zhou WP. Yang S, et al. Among authors: yuan sx. J Cancer Res Clin Oncol. 2014 Jan;140(1):109-16. doi: 10.1007/s00432-013-1536-8. Epub 2013 Nov 17. J Cancer Res Clin Oncol. 2014. PMID: 24240726

3

Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels.

Huang G, Lau WY, Zhou WP, Shen F, Pan ZY, Yuan SX, Wu MC. Huang G, et al. JAMA Surg. 2014 Jun;149(6):519-27. doi: 10.1001/jamasurg.2013.4648. JAMA Surg. 2014. PMID: 24696192

4

Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling.

Yang Y, Zhao LH, Huang B, Wang RY, Yuan SX, Tao QF, Xu Y, Sun HY, Lin C, Zhou WP. Yang Y, et al. Mol Carcinog. 2015 Dec;54(12):1584-95. doi: 10.1002/mc.22231. Epub 2014 Oct 12. Mol Carcinog. 2015. PMID: 25307746

5

Ligand-directed stearic acid grafted chitosan micelles to increase therapeutic efficacy in hepatic cancer.

Yang Y, Yuan SX, Zhao LH, Wang C, Ni JS, Wang ZG, Lin C, Wu MC, Zhou WP. Yang Y, et al. Mol Pharm. 2015 Feb 2;12(2):644-52. doi: 10.1021/mp500723k. Epub 2015 Jan 2. Mol Pharm. 2015. PMID: 25495890

6

Epigenetically silenced long noncoding-SRHC promotes proliferation of hepatocellular carcinoma.

Zheng H, Yang S, Yang Y, Yuan SX, Wu FQ, Wang LL, Yan HL, Sun SH, Zhou WP. Zheng H, et al. Among authors: yuan sx. J Cancer Res Clin Oncol. 2015 Jul;141(7):1195-203. doi: 10.1007/s00432-014-1871-4. Epub 2014 Dec 16. J Cancer Res Clin Oncol. 2015. PMID: 25512078

7

Long noncoding RNA, the methylation of genomic elements and their emerging crosstalk in hepatocellular carcinoma.

Yuan SX, Zhang J, Xu QG, Yang Y, Zhou WP. Yuan SX, et al. Cancer Lett. 2016 Sep 1;379(2):239-44. doi: 10.1016/j.canlet.2015.08.008. Epub 2015 Aug 14. Cancer Lett. 2016. PMID: 26282784 Review.

8

EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.

Gu F, Yuan S, Liu L, Zhu P, Yang Y, Pan Z, Zhou W. Gu F, et al. Among authors: yuan s. J Cell Mol Med. 2019 Jun;23(6):4208-4216. doi: 10.1111/jcmm.14309. Epub 2019 Apr 7. J Cell Mol Med. 2019. PMID: 30957411 Free PMC article.

9

Minimally invasive surgery of malignancies: time to argue the fundamental reasons for this emerging technique.

Yuan S, Zhou W. Yuan S, et al. Hepatobiliary Surg Nutr. 2020 Apr;9(2):195-197. doi: 10.21037/hbsn.2020.02.01. Hepatobiliary Surg Nutr. 2020. PMID: 32355677 Free PMC article. No abstract available.

10

NQO1 promotes an aggressive phenotype in hepatocellular carcinoma via amplifying ERK-NRF2 signaling.

Yang Y, Zheng J, Wang M, Zhang J, Tian T, Wang Z, Yuan S, Liu L, Zhu P, Gu F, Fu S, Shan Y, Pan Z, Zhou W. Yang Y, et al. Among authors: yuan s. Cancer Sci. 2021 Feb;112(2):641-654. doi: 10.1111/cas.14744. Epub 2020 Dec 13. Cancer Sci. 2021. Retraction in: Cancer Sci. 2023 Jul;114(7):3057. doi: 10.1111/cas.15809 PMID: 33222332 Free PMC article. Retracted.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,648 results

Search Page

Filters